» Articles » PMID: 38181751

Kidney Organoid Models Reveal Cilium-autophagy Metabolic Axis As a Therapeutic Target for PKD Both In vitro and In vivo

Abstract

Human pluripotent stem cell-derived kidney organoids offer unprecedented opportunities for studying polycystic kidney disease (PKD), which still has no effective cure. Here, we developed both in vitro and in vivo organoid models of PKD that manifested tubular injury and aberrant upregulation of renin-angiotensin aldosterone system. Single-cell analysis revealed that a myriad of metabolic changes occurred during cystogenesis, including defective autophagy. Experimental activation of autophagy via ATG5 overexpression or primary cilia ablation significantly inhibited cystogenesis in PKD kidney organoids. Employing the organoid xenograft model of PKD, which spontaneously developed tubular cysts, we demonstrate that minoxidil, a potent autophagy activator and an FDA-approved drug, effectively attenuated cyst formation in vivo. This in vivo organoid model of PKD will enhance our capability to discover novel disease mechanisms and validate candidate drugs for clinical translation.

Citing Articles

Advances and Challenges in Modeling Autosomal Dominant Polycystic Kidney Disease: A Focus on Kidney Organoids.

Gu J, Liu F, Li L, Mao J Biomedicines. 2025; 13(2).

PMID: 40002937 PMC: 11852630. DOI: 10.3390/biomedicines13020523.


Targeting TRPM3 as a potential therapeutic approach for autosomal dominant polycystic kidney disease.

Gul H, Davies J Sci Rep. 2025; 15(1):4714.

PMID: 39922884 PMC: 11807189. DOI: 10.1038/s41598-025-89200-z.


Trends and challenges in organoid modeling and expansion with pluripotent stem cells and somatic tissue.

Ge J, Wang Y, Li Q, Liu F, Lei Q, Zheng Y PeerJ. 2024; 12:e18422.

PMID: 39619184 PMC: 11608026. DOI: 10.7717/peerj.18422.


Low-dose tolvaptan to control disease progression in Chinese patients with autosomal dominant polycystic kidney disease: a retrospective cohort study.

Zhou L, Wei X, Wang B, Xu Q, Li W Transl Androl Urol. 2024; 13(10):2307-2321.

PMID: 39507867 PMC: 11535741. DOI: 10.21037/tau-24-448.


Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.

Yao Q, Cheng S, Pan Q, Yu J, Cao G, Li L MedComm (2020). 2024; 5(10):e735.

PMID: 39309690 PMC: 11416091. DOI: 10.1002/mco2.735.